-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Science and Technology Daily, Beijing, January 23 (Intern reporter Zhang Jiaxin) According to a paper published in the journal "Nature Communications" on the 20th, scientists from Northwestern University School of Medicine and the University of Texas MD Anderson Cancer Center found in preclinical research that, A natural nano-sized bubble containing angiotensin-converting enzyme 2 protein, evACE2, exists in the blood of patients with new coronary pneumonia and has been found to prevent infection of a wide range of new coronavirus strains, including current multiple new coronavirus variants and possible future coronaviruses
The evACE2 protein is a nanoparticle-sized tiny lipid (fat) vesicle that expresses the ACE2 protein (the receptor for the novel coronavirus)
The new coronavirus spike protein "grabs" the "handle" of evACE2, not ACE2 inside the cell, a process that prevents the virus from entering human cells
The key to the study was the identification of naturally occurring extracellular vesicles in the body that express the ACE2 receptor on their surface, said study co-senior author Ragu Caluri, Ph.
This study shows for the first time that the evACE2 protein can fight the new coronavirus variant with the same or better effect of blocking the original strain
"Whenever new SARS-CoV-2 variants proliferate, initial vaccines and therapeutic antibodies may become resistant to alpha, beta, delta, and the latest Omicron variants
Studies in mice show that evACE2 has therapeutic potential to prevent or block infection when the new coronavirus is transmitted to the airways through droplets
One of the biggest challenges in fighting the COVID-19 pandemic is the moving target of the virus, which is constantly evolving into new virus strains (variants) with mutations
Currently, the team is applying for patents on evACE2 with the goal of working with industry partners to develop evACE2 as a biotherapeutic product (nasal spray or injection therapy) for the prevention and treatment of COVID-19
